Silo Pharma Announces Planned SAD and MAD Studies for Intranasal PTSD and Anxiety Treatment

Silo Pharma has entered into a non-binding Letter of Intent with Allucent to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subjects. The studies aim to assess the safety and efficacy of the drug for treating PTSD and anxiety. Allucent will provide services for clinical operations, pharmacovigilance, and data management. The LOI marks a key inflection point in the development of Silo's intranasal PTSD and anxiety treatment.